$231 Million is the total value of Aisling Capital Management LP's 15 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPRB | Exit | Spruce Biosciences, Inc. (SPRB) | $0 | – | -1,205,511 | -100.0% | -0.32% | – |
| AVRO | Exit | Avrobio, Inc. (AVRO) | $0 | – | -1,009,779 | -100.0% | -0.44% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 23 | Q2 2024 | 23.0% |
| Aclaris Theraputics Inc. (ACRS) | 23 | Q2 2024 | 6.6% |
| AVROBIO, Inc. (AVRO) | 22 | Q1 2024 | 13.6% |
| BridgeBio Pharma Inc. (BBIO) | 21 | Q2 2024 | 73.1% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| Atreca Inc. (BCEL) | 19 | Q4 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 18 | Q2 2024 | 17.2% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| POSEIDA THERAPEUTICS INC (PSTX) | 16 | Q2 2024 | 3.6% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-21 |
| 13F-HR | 2024-08-08 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.